Analysts expect TG Therapeutics Inc (NASDAQ:TGTX) to report sales of $40,000.00 for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for TG Therapeutics’ earnings. TG Therapeutics also posted sales of $40,000.00 in the same quarter last year. The business is scheduled to report its next quarterly earnings results on Thursday, March 14th.
On average, analysts expect that TG Therapeutics will report full year sales of $160,000.00 for the current year, with estimates ranging from $150,000.00 to $200,000.00. For the next fiscal year, analysts anticipate that the business will report sales of $170,000.00, with estimates ranging from $150,000.00 to $200,000.00. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for TG Therapeutics.
Several brokerages have recently issued reports on TGTX. BidaskClub upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. ValuEngine downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, February 28th. Zacks Investment Research upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a research report on Wednesday, February 6th. Jefferies Financial Group restated a “buy” rating and set a $8.00 price objective on shares of TG Therapeutics in a research report on Wednesday, February 6th. Finally, HC Wainwright restated a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, January 22nd. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. TG Therapeutics currently has an average rating of “Buy” and an average price target of $13.58.
A number of hedge funds and other institutional investors have recently bought and sold shares of TGTX. Great Point Partners LLC increased its position in TG Therapeutics by 53.8% during the 4th quarter. Great Point Partners LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock valued at $12,300,000 after purchasing an additional 1,050,000 shares during the period. Two Sigma Investments LP grew its position in shares of TG Therapeutics by 312.9% in the 4th quarter. Two Sigma Investments LP now owns 769,011 shares of the biopharmaceutical company’s stock worth $3,153,000 after buying an additional 582,771 shares during the last quarter. venBio Select Advisor LLC grew its position in shares of TG Therapeutics by 13.1% in the 4th quarter. venBio Select Advisor LLC now owns 4,750,000 shares of the biopharmaceutical company’s stock worth $19,475,000 after buying an additional 549,969 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of TG Therapeutics in the 3rd quarter worth approximately $1,974,000. Finally, BlackRock Inc. grew its position in shares of TG Therapeutics by 8.3% in the 3rd quarter. BlackRock Inc. now owns 4,420,852 shares of the biopharmaceutical company’s stock worth $24,757,000 after buying an additional 339,802 shares during the last quarter. 59.04% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ TGTX traded up $0.15 during midday trading on Monday, hitting $6.95. 2,426,530 shares of the company traded hands, compared to its average volume of 2,064,339. The stock has a market capitalization of $603.48 million, a P/E ratio of -3.64 and a beta of 2.29. TG Therapeutics has a 12-month low of $3.32 and a 12-month high of $16.85.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
Further Reading: Trading Ex-Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.